Novel pharmacotherapies to abrogate postinfarction ventricular remodeling

Keyphrases

• Myocardial Infarction 100%
• Post-infarction 100%
• Ventricular Remodeling 100%
• Novel Pharmacotherapy 100%
• Cardiomyocytes 66%
• Cell-based 33%
• Apoptosis 33%
• Human Disease 33%
• Heart Failure 33%
• Molecular Pathways 33%
• Multiple Organs 33%
• Infarction 33%
• Dropout 33%
• Cellular Pathways 33%
• Kinase Inhibition 33%
• Therapeutic Targeting 33%
• Endothelial Nitric Oxide Synthase (eNOS) 33%
• Pharmaceutics 33%
• Putative Drug Targets 33%
• Wall Thinning 33%
• G Protein-coupled Receptor Kinase 33%
• Therapeutic Window 33%
• Inflammatory Fibrosis 33%
• Erythropoietin 33%
• Pharmacological Treatment 33%
• Ventricular Geometry 33%
• Active Processes 33%
• Cardiac Outcomes 33%
• Renin-angiotensin-aldosterone System 33%
• Physiological Pathways 33%
• Functional Compromise 33%
• Direct Renin Inhibition 33%
• Aldosterone Synthesis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Heart Infarction 100%
• Pharmacotherapy 100%
• Heart Ventricle Remodeling 100%
• Aldosterone 66%
• Receptor 33%
• Phosphotransferase 33%
• Renin 33%
• Angiotensin 33%
• Inflammation 33%
• Fibrosis 33%
• Infarction 33%
• Congestive Heart Failure 33%
• Guanine Nucleotide Binding Protein 33%
• Therapeutic Window 33%
• Endothelial Nitric Oxide Synthase 33%
• Erythropoietin 33%
• Renin Inhibitor 33%
• Diseases 33%